マスオーガノイドのフェノタイプ化は,代謝に関連したNASHに対する遺伝的感受性を告げる
Masaki Kimura1, Takuma Iguchi1, Kentaro Iwasawa1
1Division of Gastroenterology, Hepatology and Nutrition, Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Cell
|October 14, 2022
まとめ
人間のオルガノイドを用いた非アルコール性脂肪肝炎 (NASH) の遺伝子の調査は,GCKR-rs1260326の変異体が代謝状態に基づいて疾患の重さに異なる影響を及ぼし,新しい治療的洞察を提供することを明らかにした.
科学分野:
- 遺伝学とゲノミクス
- 代謝 疾患
- オルガノイド技術
背景:
- 非アルコール性脂肪肝炎 (NASH) のゲノタイプ-フェノタイプ関連が,ヒトのオーガノイドパネルを組み合わせて調査された.
- メタボリック状態,特にインスリン不敏感性,遺伝因子の予測への影響に焦点を当てた.
関連する概念動画
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


